ZYBERNO
Stock Report
Updated Aug 31, 2026

YD Bio Limited (YDES)

Healthcare • NASDAQ

$4.80

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
6.0/100
POOR BUSINESS
YD Bio Limited (YDES) scores 6/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (0.0%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-50.9%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

YD Bio Limited (YDES) stock report — Zyberno Score 6/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:4.80
Market Cap:$320.25M

Valuation Multiples (2)

P/S Ratio:536.60x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$314.69M

Price Action & Momentum (1)

% of 52-Week High:19.2%
B. Profitability Assessment

Return Metrics (3)

Reinvestment Rate:-36.0%
Fundamental Growth Rate (g):18.3%

Margin Analysis (1)

Ebitda Margin:-880.6%

Yield Metrics (2)

Earnings Yield:-$999.00
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:5.88x
Quick Ratio:4.74x
Cash Ratio:3.66x

Leverage Analysis (1)

Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-6,828.65x
Times Interest Earned:-6,828.65

Capital Structure (4)

Working Capital:8,026,612.00
Cash And Cash Equivalents:6,007,615.00
Long Term Debt:$6.76K
Net Debt:-$5.56M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$596.82K
Cost Of Revenue Ttm:$429.41K

Profitability Breakdown (2)

$167.41K-$5.27M

Bottom Line Performance (3)

-$8.31M
Income Before Tax:-$8.31M
Ebitda Ttm:-5,255,475.00

Operating Expenses (5)

Operating Expenses:5,439,131.00
R And D Expense:1,602,064.00
Sga Expense:3,663,141.00
Income Tax Expense:-$1.53K
Interest Expense:772.00

Expense Ratios (3)

R And D To Revenue Percentage:268.4%
Sga To Revenue Percentage:613.8%
Ebitda Margin:-880.6%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$13.78M
Current Assets:$9.67M
Ppe Net:59,340.00
Goodwill:0.00
Intangible Assets:$2.61M

Liability Structure (4)

Total Liabilities:16,635,060.00
Current Liabilities:1,643,578.00
Long Term Debt:$6.76K
Short Term Debt:$437.86K

Equity & Capital (3)

Equity:-$2.86M
Retained Earnings:-$10.24M
Common Stock:500,000,000.00

Working Capital Items (3)

Accounts Receivable:167,477.00
Inventory:1,879,542.00
Accounts Payable:413,290.00

Special Items (2)

Contract Liabilities:30,153.00
Stock Based Compensation:0.00
C. Cash Flow Analysis

Operating Activities (2)

-$6.60M-$8.04M

Investment Activities (1)

Investing Cash Flow:-$1.44M

Financing Activities (3)

Financing Cash Flow:$10.87M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:13,200,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$32.98K

Non-Cash Items (1)

Depreciation Amortization Ttm:16,246.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (1)

Earnings Per Share Ttm:-$0.12

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.01
Operating Cash Flow Per Share:-$0.10

Book Value & Capital (2)

Book Value Per Share:-$0.04
Cash Per Share:0.09

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:0.04x
Working Capital Turnover Ttm:0.07x

Receivables Management (2)

Receivables Turnover Ttm:3.56x
Days Sales Outstanding Ttm:102.43

Inventory Management (2)

Inventory Turnover Ttm:0.23x
Days Inventory Outstanding Ttm:1,597.63

Payables & Cash Cycle (2)

Days Payable Outstanding:351.30
Cash Conversion Cycle:1,348.75
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:60.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:-36.0%
Fundamental Growth Rate (g):18.3%
B. Log-Linear Regression Growth Analysis
C. Company Profile & Context

Corporate Information (6)

Symbol:YDES
Company Name:YD Bio Limited
Sector:Healthcare
Industry:Services-Medical Laboratories
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:low
Volume Category:N/A

Share Structure (3)

Shares Outstanding:66.72M
Shares Outstanding Basic:66.72M
Shares Outstanding Diluted:66.72M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 07:57:14 UTC
Data Timestamp:2026-08-18T20:47:40.113486
Scroll to Top